Insufficient enrolments. This was mentioned at one stage for the P2 BCBM trial run by Jose Pablo Leone. Also I don't think that interim readout of the Pax single treatment DIPG trial was showing any overall survival extension so I'm not confident on that (which is why mobbing it to combo trials will hopefully be better). But I am expecting positive results from the Alliance trial that has recently progressed the Pax arm
